InSightec developed ExAblate® 2000– a product that integrates Magnetic Resonance Imaging (MRI) with focused ultrasound energy - as a new treatment modality that can replace invasive procedures and provide therapeutic alternatives to millions of patients with serious diseases around the globe.
ExAblate was approved by the U.S. Food and Drug Administration (FDA) in October 2004 to treat symptomatic uterine fibroids and to date over 3000 women have been treated worldwide for symptomatic uterine fibroids. InSightec has begun clinical trials to study the technology’s use in other indications including breast, bone, liver and brain tumors. 
ExAblate also received the European CE mark for treating pain palliation caused by bone metastatses.InSightec was founded in 1999 when GE Healthcare (then GE Medical Systems) and Elbit Medical Imaging transferred their proprietary technology to the company to enable it to concentrate on developing the promising MR guided focused ultrasound surgery both companies had investigated. Since then, InSightec has invested over $100 million in research and development. The company holds over 30 patents with additional intellectual property pending.